Rocket Pharmaceuticals, Inc. Finite-Lived Intangible Assets, Accumulated Amortization
Rocket Pharmaceuticals, Inc. (RCKT) had Finite-Lived Intangible Assets, Accumulated Amortization of $0 as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization · last filed 2026-02-26
- 2025-12-31: Finite-Lived Intangible Assets, Accumulated Amortization $0.00.
- 2024-12-31: Finite-Lived Intangible Assets, Accumulated Amortization $0.00.
| Period end | Finite-Lived Intangible Assets, Accumulated Amortization |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |